Select a country from the regions above then, add your country to our comparison tool to compare country specific information simultaneously across 3 countries
Indonesia
Fast Facts
Capital: Jakarta
Economy: 17th largest in the world, nominal GDP US$845 billion, 2011
Health Expenditure: 1.9% of GDP, 2011
Population: 237 million, 2011
Average Life Span: 71, 2011
Languages: Bahasa Indonesian
Adult Literacy Rate: 92% 2011
Health Trends
The Indonesian pharmaceutical market was estimated at U.S. $2.7 billion in 2007 and is expected to increase to U.S. $4.2 billion by 2012.
Access to health care is not developed, hence the availability of treatment naïve patients or undiagnosed cases.
Tertiary and teaching hospitals are predominantly used for clinical trials.
According to WHO, Cancer mortality is reported the highest across the South East Asia region with a figure of 6.6 percent
Leading causes of death: Ischemia, Hypertension, Cerebrovascular diseases, LRTI, COPD, DM, TB, Road Traffic Accidents and Diarrheal diseases.
Clinical Trial Landscape
Large patient population base.
Submission to Local EC and HA completed sequentially.
For global trials requiring the shipping of biological samples to a central laboratory outside of Indonesia, the Materials Transfer Agreements needs to undergo MOHR (Litbangkes – Health Research and Development of Ministry of Health) review and approval.
Not all physicians are well trained on ICH-GCP, hence selection of interested and experienced investigators are key to success of clinical trials.
Indonesian investigators require more CRA support compared to other countries. Culturally, face-to-face meetings are usually preferred by Investigators with CRAs.